Rhythm Biosciences (FRA:0RY) Total Equity: €1.22 Mil (As of Dec. 2025)


FRA:0RY Rhythm Biosciences Ltd FRA:0RY
31 GF Score
Price €0.06
! 5 Warning Signs
View Full Analysis

What is Rhythm Biosciences Total Equity?

Rhythm Biosciences FRA:0RY -1.74% 31 Total Equity is €1.22 Mil as of Dec. 2025. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

Rhythm Biosciences's total equity for the quarter that ended in Dec. 2025 was €1.22 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Rhythm Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences Total Equity Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial 1.08 4.90 3.64 0.54 0.37

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.54 2.95 0.37 1.22
FRA:0RY
31GF Score
Rhythm Biosciences Ltd FRA:0RY
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Rhythm Biosciences's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=1.599-1.226
=0.37

Rhythm Biosciences's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1.759-0.542
=1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1.22 Mil mean?
Rhythm Biosciences (FRA:0RY) has a Total Equity of €1.22 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Rhythm Biosciences and its competitors.
Is Rhythm Biosciences' Total Equity too high?
Rhythm Biosciences' current Total Equity is €1.22 Mil. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Total Equity compare to TMO and DHR?
Rhythm Biosciences' Total Equity of €1.22 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Rhythm Biosciences and its competitors. Rhythm Biosciences's current Total Equity is €1.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Total Equity of €1.22 Mil. The current Total Equity is €1.22 Mil. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Total Equity is €1.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Other Exchanges RHY:Australia
Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score

Get the complete analysis for FRA:0RY

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price